Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Shadow-Mode Evaluation of an AI Assistant for Multidisciplinary Tumor Boards (OnkoBot)

9 novembre 2026 aggiornato da: Lisa Adams, Technical University of Munich

OnkoBot: Prospective Shadow-Mode Evaluation of a Locally Operated, Source-Grounded Large Language Model System for Drafting Multidisciplinary Tumor Board Recommendations

This study tests whether an artificial intelligence (AI) system that drafts tumor board recommendations performs as well on new cases as it did on archived cases. The system runs in shadow mode at three multidisciplinary tumor boards of TUM University Hospital rechts der Isar. For each case it drafts a recommendation before the board meets. The board does not see the draft, and the draft has no influence on patient care. After the meeting, each draft is compared with the board decision. The agreement rate is then compared with the rate measured on archived decisions of the same boards.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The system is a locally operated large language model (LLM) pipeline with retrieval-augmented generation. Its input is the case as presented to the board, with diagnosis, course, question and all patient documents dated before the board date. It retrieves guideline recommendations (Onkopedia and AWMF S3 guidelines in the version in force on the board date), laboratory values, precedent cases from the board archive and PubMed abstracts published before the board date. It then drafts a recommendation with justification. Each statement of the draft is linked to a verbatim quote from its source. All models run on local GPU servers of the hospital with no data retention beyond the immediate analysis, and no patient data are sent to external providers.

The study includes the hematology board, the orthopedics and sarcoma board and the head and neck board. For each case registered for a session, the system drafts a recommendation after the pre-board documents are pulled and before the session starts. Board members do not see the drafts. The decision pipeline (generator Gemma-4-31B at temperature 0) is frozen and versioned for the study period. The study uses routine clinical data only. Patients are not contacted, and no study-specific procedures are performed.

The draft is compared with the consensus decision in the board report. An LLM judge (GLM-5.3-Flash, majority of three votes) assigns both texts to one of seven decision categories: systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care and referral to the molecular tumor board. It also scores agreement in substance from 0 to 3 and records the direction of any disagreement. The judge was validated against clinician ratings on a sealed test set. The same prompt version is used to score the prospective cases and the retrospective reference sample, separately from any output that clinicians see.

The retrospective reference is the evaluation sample of archived decisions of the same three boards (about 2,000 cases, one per patient, drawn with a fixed seed and stratified by time). Patients who also appear in the prospective cohort are removed from the reference. The primary analysis tests non-inferiority of the prospective category match rate against the retrospective rate, pooled over the three boards, with a margin of 7.5 percentage points and a one-sided alpha of 0.025. The variance is cluster-robust for board sessions. A case without a draft counts as not concordant. Per-board results are reported descriptively with 95% confidence intervals. An exploratory component evaluates a trial-matching engine that proposes recruiting clinical trials per case.

In a subset of 30 to 50 cases per board, physicians rate the system draft against the board decision. This subset tests whether the agreement between judge and clinicians, measured retrospectively, also holds prospectively.

Tipo di studio

Osservativo

Iscrizione (Stimato)

450

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Bavaria
      • Munich, Bavaria, Germania, 81675
        • Non ancora reclutamento
        • TUM University Hospital rechts der Isar
      • Munich, Bavaria, Germania
        • Reclutamento
        • TUM Klinikum rechts der Isar
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino
  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

All cases registered for the hematology, orthopedics and sarcoma, and head and neck tumor boards of TUM University Hospital rechts der Isar during the study period. One case is one patient presentation on one board date.

Descrizione

Inclusion Criteria:

  • Case registered for a session of a participating tumor board (hematology, orthopedics and sarcoma, head and neck) of TUM University Hospital rechts der Isar during the study period
  • Board registration and pre-board patient documents available before the session starts

Exclusion Criteria:

  • Case not discussed at the session, defined as no board report with a consensus decision for that date (deferred or withdrawn registrations)
  • Session without a shadow run of the system

Excluded cases are counted and reported by reason.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: PROSPECTIVE

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Hematology board

Consecutive cases presented at the hematology tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Orthopedics and sarcoma board

Consecutive cases presented at the orthopedics and sarcoma tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Head and neck board

Consecutive cases presented at the head and neck tumor board of TUM University Hospital rechts der Isar.

A locally operated, source-grounded large language model system drafts a tumor board recommendation with justification and verified citations for each case before the board meeting. The draft is not shown to the board and does not influence patient care.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Cases With Category Match Between System Draft and Board Decision
Lasso di tempo: Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of discussed cases in which the system draft and the board consensus decision fall into the same of seven decision categories (systemic therapy, surgery, radiotherapy, watch and wait, further diagnostics, best supportive care, referral to the molecular tumor board). Overlap counts where either side carries a second category. Assessed by a pre-specified LLM judge (GLM-5.3-Flash, prompt V3, majority of three votes), pooled over the three boards. Tested for non-inferiority against the rate of the same system and judge on the retrospective reference sample of the same boards, margin 7.5 percentage points, one-sided alpha 0.025.

Each case is assessed once, after the board report of its session is available; analysis after accrual is complete (anticipated January 2027)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of Cases Rated Concordant or Partially Concordant
Lasso di tempo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match with a substance score of at least 1 of 3 (concordant requires at least 2 of 3 on a primary-category match, 3 of 3 where only second categories overlap). Non-inferiority versus retrospective reference, margin 7.5 percentage points, tested after the primary outcome (hierarchical testing).

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases Rated Concordant, Partially Concordant and Not Concordant
Lasso di tempo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Proportion of cases rated concordant, partially concordant and not concordant by the LLM judge.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match per Board
Lasso di tempo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Category match and concordant or partially concordant per board, with 95% confidence intervals, descriptive.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Discordant Cases by Direction of Disagreement
Lasso di tempo: After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)

Among cases without category match, proportion in which the draft is more conservative, more aggressive or a different modality than the board decision.

After the board report of each session is available; analysis after accrual is complete (anticipated January 2027)
Proportion of Cases With Category Match as Rated by Clinicians
Lasso di tempo: Within 3 months after the board session

In 30 to 50 cases per board, agreement between draft and board decision as rated by physicians who did not attend the session, and agreement between judge and clinicians on category match (percentage agreement, Cohen's kappa).

Within 3 months after the board session
Proportion of Citations Verified Word for Word Against Their Source
Lasso di tempo: At draft generation, before the board session

Proportion of citations per case that verify word for word against their source, and proportion of cases in which every citation verifies.

At draft generation, before the board session
Proportion of Cases With a Draft Completed Before the Board Session
Lasso di tempo: At draft generation, before the board session

Proportion of cases with a draft completed before the session starts, and generation time per case in minutes.

At draft generation, before the board session

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Clinical Trials Shortlisted per Case by the Trial-Matching Engine
Lasso di tempo: At draft generation, before the board session

Number of trials shortlisted per case, proportion recruiting on the board date, rule-based error rate (wrong disease, line of therapy, setting or status) and clinician screening verdicts where given.

At draft generation, before the board session

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Lisa Adams, MD, Technical University of Munich
  • Investigatore principale: Krischan Braitsch, MD, Technical University of Munich

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

9 novembre 2026

Completamento primario (Stimato)

31 gennaio 2027

Completamento dello studio (Stimato)

30 aprile 2027

Date di iscrizione allo studio

Primo inviato

9 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

9 novembre 2026

Primo Inserito (Effettivo)

16 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ONKOBOT-SHADOW-01
  • KK6050201BM5 (Altro numero di sovvenzione/finanziamento: Central Innovation Programme for SMEs (ZIM), German Federal Ministry for Economic Affairs)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data are routine clinical records that may not leave the hospital under the ethics approval and data protection concept. Aggregate results and the analysis code will be published.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .